

A Guide to Getting Started with ZILBRYSQ® (zilucoplan) Injection for Subcutaneous Use

Please see Important Safety Information about ZILBRYSQ at the end of this document.

ONWARD® is provided as a service of UCB and is intended to support the appropriate use of UCB medicines.

ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

ZILBRYSQ® and ONWARD® are registered trademarks of the UCB Group of Companies.

All other trademarks are the property of their respective holders.

©2025 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-ZL-2400318



GETTING STARTED:
☐ Add your ONWARD® Care Coordinator's (OCC) contact information to your cell phone contacts to stay in touch.
☐ Schedule a call with your OCC to understand your insurance coverage and potential financial assistance eligibility.
☐ Ensure you have a plan with your HCP to receive all required vaccinations to support your start on ZILBRYSQ. The Specialty Pharmacy cannot ship until you have received them.
☐ Review your Demo Device Kit.
If you were not offered a Demo Device Kit by your HCP, contact us and we will ship it to your home.
PREPARING FOR YOUR FIRST INJECTION:
After insurance benefits are confirmed, your shipment of ZILBRYSQ will be processed and sent to you by the Specialty Pharmacy, PANTHERx Rare. Expect a phone call from 833-418-7760 to coordinate delivery.
☐ Coordinate delivery with the Specialty Pharmacy. Remember, you'll need to speak with a
pharmacy representative by phone.
☐ Schedule Injection Refresher Training with your OCC, if needed.
\square Invite a caregiver to join for support.
☐ Request a Demo Device Kit.
Please see Important Safety Information about ZILBRYSQ on page 3.

A Guide to Getting Started

with ZILBRYSQ® (zilucoplan) Injection for Subcutaneous Use



☐ Set up your inject	ion location:
☐ Find a cle	ean, quiet place.
	ILBRYSQ in advance, especially if you stored it in the refrigerator. It needs to be at perature.
	ne materials you need, such as cotton balls, alcohol wipe, adhesive bandage, and a sposal or puncture-resistant container for easy and appropriate disposal.
☐ Consider	adding things that make you feel at ease, like music or aromatherapy.
AFTER YOUR FIRST	TREATMENT:
☐ Review how your i make for your nex	njection process went and think about whether there are any changes you want to t injection.
☐ Please reach out t	to your HCP for any questions or concerns related to your treatment.
treatment to	will reach out during your to check in—and is always o listen if you'd like to things are going!

Please see Important Safety Information about ZILBRYSQ on the next page.

Continued ¬



A Guide to Getting Started with ZILBRYSQ® (zilucoplan) Injection for Subcutaneous Use



IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING

ZILBRYSQ is a medicine that affects part of your immune system. ZILBRYSQ may lower the ability of your immune system to fight infections. ZILBRYSQ increases your chance of getting serious meningococcal infections caused by Neisseria meningitidis bacteria. Meningococcal infections may quickly become life-threatening or cause death if not recognized and treated early. You must complete or update your meningococcal vaccine(s) at least 2 weeks before your first dose of ZILBRYSQ. If you have not completed your meningococcal vaccines and ZILBRYSO must be started right away, you should receive the required vaccine(s) as soon as possible. If you have not been vaccinated and ZILBRYSQ must be started right away, you should also receive antibiotics to take for as long as your healthcare provider tells you. If you had a meningococcal vaccine in the past, you might need additional vaccines before starting ZILBRYSQ. Your healthcare provider will decide if you need additional meningococcal vaccines. Meningococcal vaccines do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection:

fever, fever and a rash, fever with high heart rate, headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, confusion, eyes sensitive to light, and muscle aches with flu-like symptoms.

Your healthcare provider will give you a **Patient Safety Card about the risk of serious** meningococcal infection. Carry it with you at all times during treatment and for 2 months after your last ZILBRYSQ dose. Your risk of meningococcal infection may continue for several weeks after your last dose of ZILBRYSQ. It is important to show this card to any healthcare provider who treats you. This will help them diagnose and treat you quickly. ZILBRYSQ is only available through a program called the ZILBRYSQ Risk Evaluation and Mitigation Strategy (REMS). Before you can receive ZILBRYSQ, your healthcare provider must: enroll in the ZILBRYSQ REMS program; counsel you about the risk of meningococcal infections; give you the Patient Guide, including information about the signs and symptoms of meningococcal infection; give you a **Patient Safety Card** about your risk of meningococcal infection, as discussed above;

A Guide to Getting Started with ZILBRYSQ® (zilucoplan) Injection for Subcutaneous Use



IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING (cont.)

make sure that you are vaccinated against serious infections caused by meningococcal bacteria and that you receive antibiotics if you need to start ZILBRYSQ right away and you are not up to date on your vaccines.

ZILBRYSQ may also increase the risk of other types of serious infections caused by encapsulated bacteria, including *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria gonorrhoeae*. Certain people may be at risk of serious infections with gonorrhea. Talk to your healthcare provider about whether you are at risk for gonorrhea infection, about gonorrhea prevention, and about regular testing. Call your healthcare provider right away if you have new signs or symptoms of infection.

Do not use ZILBRYSQ if you have a serious meningococcal infection when you are starting ZILBRYSQ treatment.

Before you use ZILBRYSQ, tell your healthcare provider about all of your medical conditions, including if you have an infection or fever; are pregnant or plan to become pregnant; or are

breastfeeding or plan to breastfeed. **Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, vitamins, and herbal supplements.

In addition to increasing your chance of getting serious meningococcal infections, ZILBRYSQ may also cause inflammation of the pancreas (pancreatitis) and other pancreatic problems. Pancreatitis and pancreatic cysts have happened in people who use ZILBRYSQ. Your healthcare provider will do blood tests to check your pancreas before you start treatment with ZILBRYSQ. Call your healthcare provider right away if you have pain in your stomach area (abdomen) that will not go away. Your healthcare provider will tell you if you should stop using ZILBRYSQ. The pain may be severe or felt going from your abdomen to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.

The most common side effects of ZILBRYSQ include injection site reactions, upper respiratory tract infections, and diarrhea.

A Guide to Getting Started with ZILBRYSQ® (zilucoplan)

Injection for Subcutaneous Use



IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING (cont.)

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ZILBRYSQ. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or 1-800-FDA-1088. You may also report side effects to UCB, Inc. by calling 1-844-599-CARE [2273].

See the detailed Instructions for Use that comes with ZILBRYSQ for information on how to prepare and inject a dose of ZILBRYSQ, and how to properly throw away (dispose of) used ZILBRYSQ prefilled syringes.

ZILBRYSQ is a prescription medicine used to treat adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. It is not known if ZILBRYSQ is safe and effective in children.

Please see the full Prescribing Information and Medication Guide for ZILBRYSQ, including the Boxed

Warning regarding serious meningococcal infections. Please see the Instructions for Use for the ZILBRYSQ Single-Dose Prefilled Syringe. Talk to your healthcare provider about your condition or your treatment. For more information, go to www.ZILBRYSQ.com or call 1-844-599-2273.